Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Genprex ( (GNPX) ).
On June 23, 2025, Genprex announced positive preclinical data for its diabetes gene therapy drug candidate, GPX-002, presented at the 2025 American Diabetes Association Scientific Sessions. The research explored a non-viral lipid nanoparticle delivery system, which could allow repeat dosing without the need for immunosuppression, marking a significant step in the company’s diabetes program. The findings provide proof of concept for further studies and suggest a potential next-generation approach for treating Type 1 diabetes, enhancing Genprex’s position in the biotechnology field.
The most recent analyst rating on (GNPX) stock is a Buy with a $7.50 price target. To see the full list of analyst forecasts on Genprex stock, see the GNPX Stock Forecast page.
More about Genprex
Genprex, Inc. operates in the biotechnology industry, focusing on the development of gene therapies for diseases such as cancer and diabetes. The company is working on innovative treatments, including GPX-002, a diabetes gene therapy drug candidate, utilizing advanced delivery systems.
Average Trading Volume: 3,801,515
Technical Sentiment Signal: Sell
Current Market Cap: $7.66M
For an in-depth examination of GNPX stock, go to TipRanks’ Overview page.